Welcome to call or send an email!
Petra Larson, Communications lead
+46 (0)709 13 10 08
petra.larson@pharmnovo.com
CONNECT WITH US
Get in touch
Welcome to call or send an email!
Petra Larson, Communications lead
+46 (0)709 13 10 08
petra.larson@pharmnovo.com
Find us: PharmNovo AB, Medicon Village AB, Scheeletorget 1, SE-223 81 Lund, Sweden
Take the opportunity to listen to Per von Mentzer, CEO, presenting PN6047 at the LSX World Europe congress in Lisbon, March 2026. Learn how PharmNovo is shaping a new approach to pain relief with the goal to prove that powerful pain treatment doesn’t have to come with the cost of addiction. Discover how the company’s lead candidate PN6047, delivers effective pain relief without activating the mu-opioid receptor and avoiding the addiction risks associated with conventional opioids. The Phase II-ready Delta Opioid Receptor Agonist (DORA) with first-in-class potential, PN6047 represents a safer, non-addictive approach targeting a neuropathic pain market that is expected to double until 2033 and reach 13 bEUR.
Read morePharmNovo is pleased to announce that that the company has completed drug product manufacturing for its lead candidate PN6047. This is an important milestone as the company prepares for its upcoming Phase IIa proof-of-concept study in neuropathic pain.
Read moreAs the company prepares for the next phase of clinical development, the new Board composition strengthens our strategic capabilities ahead of Phase II development of our lead candidate, PN6047.
Read more
